Uro-Oncology Group in Kyushu (UROKYU)[Corporate Author] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Change in the Neutrophil-to-Eosinophil Ratio After Avelumab Maintenance for Advanced Urothelial Carcinoma: The UROKYU Study.

Furubayashi N, Minato A, Tomoda T, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Harada K, Kuroiwa K, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Anticancer Res. 2024 Apr;44(4):1675-1681. doi: 10.21873/anticanres.16966. Anticancer Res. 2024. PMID: 38537962

Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.

Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Anticancer Res. 2024 Jul;44(7):3025-3032. doi: 10.21873/anticanres.17115. Anticancer Res. 2024. PMID: 38925809

Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status.

Furubayashi N, Minato A, Tomoda T, Masaoka H, Hori Y, Kiyoshima K, Negishi T, Haraguchi Y, Koga T, Song Y, Harada K, Kuroiwa K, Seki N, Fujimoto N, Nakamura M; Uro-Oncology Group in Kyushu (UROKYU). Furubayashi N, et al. Anticancer Res. 2024 Aug;44(8):3409-3417. doi: 10.21873/anticanres.17161. Anticancer Res. 2024. PMID: 39060060

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters